A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
A phase 1/2 trial of PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.
Overview
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07147348 by BioNTech SE, with 375 participants planned, started 2025-08-27 and due to reach its primary completion in 2027-11. Interventions recorded: BNT3212 and Pumitamig.
Similar pages
not linked directly; found by shared links- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
- TrialSafety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEarly-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN